Need an oil spill lawyer? We will fight for you!
› $4.85 Billion settlement in drug case
WhyQuit, an organization that advocates quitting smoking using the cold turkey method, recently published an article that takes Pfizer to task over its latest Chantix ads. The group claims that the pharmaceutical company’s new television commercials hide information from the viewer – information that, if known, would likely dissuade most smokers from using the drug as a smoking cessation aid.
CNN reports that Pfizer is thinking about launching a clinical test to determine if Chantix can help prevent smokers from having heart attacks. Considering all the negative publicity that has surrounded the drug over the last one and a half years, it’s understandable that Pfizer would want to invest a good deal of time and money in finding some benefit … even if they locate just one slightly dubious side effect, such as a reduced risk of heart attack in people who have quit smoking.
Chantix has to be one of the most bipolar prescription drugs ever created. Every day, a search for the latest Chantix news digs up blogs written by fans of the smoking cessation drug, who often tout it as a miracle or a blessing in their struggle to become nonsmokers. Yet other users liken it to a nightmare or a curse, citing wild mood swings, disturbing dreams, and uncharacteristic thoughts of suicide.
Smoking cessation today isn’t as simple as it used to be. Years ago, smokers had a couple of choices: cold turkey or hypnotherapy. Then, as awareness about the dangers of smoking grew, thanks to efforts by the government and independent health groups, so too did the number of smoking cessation aids. First came prescription-only nicotine gum, which was quickly succeeded by a procession-soon-to-be-explosion of over-the-counter therapeutic nicotine — gum, patches, lozenges. In 1997, the FDA approved bupropion (a.k.a. Zyban/Wellbutrin) for use in smoking cessation. Meanwhile, all sorts of gadgets and gimmicks flooded the market. And then came Chantix.
George J. Lisicki, a Vietnam combat veteran and national commander for the Veterans of Foreign Wars (VFW), had harsh words for the Veterans Administration (VA) today.
“Those in the VA who failed to properly notify America’s veterans that their medication could produce fatal side effects must resign their positions,” Lisicki said. “If not, then the VA secretary must take decisive action to terminate their employment.”
Responding to widespread pressure from many congressmen, veteran’s organizations, and the general public, the Veterans Administration announced today that it would directly notify all of its veterans currently using Pfizer’s new smoking cessation drug Chantix. The number of veterans on Chantix is approximately 32,000.
This week has seen a snowballing reaction to the joint ABC/Washington Times news report about the Veterans Administration testing Chantix on soldiers with Post Traumatic Stress Disorder.
That snowball appears to be gaining speed and momentum. At least five congressman have queried the VA over the Chantix tests, and now a number of veteran’s groups are adding their voice to the chorus of anger.
On Monday ABC News and The Washington Times broke a report on the Veterans Administration testing Pfizer’s smoking cessation drug Chantix on 140 veterans suffering from Post Traumatic Stress Disorder (PTSD). The VA administered the drug to the soldiers without warning them about months-old discoveries linking Chantix to a range of neuropsychiatric behavior and illness, including depression, loss of sleep, vivid dreams, suicidal thoughts, and suicidal actions.
![[ Beasley Allen Law Firm Logo ]](http://www.chantix-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}